Dengue Research Opportunities in the Americas

被引:48
作者
Laughlin, Catherine A. [1 ]
Morens, David M. [2 ]
Cassetti, M. Cristina [1 ]
Denis, Adriana Costero-Saint [3 ]
San Martin, Jose-Luis [4 ]
Whitehead, Stephen S. [5 ]
Fauci, Anthony S. [2 ]
机构
[1] NIAID, Virol Branch, Div Microbiol & Infect Dis, NIH, Bethesda, MD 20892 USA
[2] NIAID, Off Director, NIH, Bethesda, MD 20892 USA
[3] NIAID, Parasitol & Int Programs Branch, Div Microbiol & Infect Dis, NIH, Bethesda, MD 20892 USA
[4] Pan Amer Hlth Org, Reg Advisor Dengue, San Jose, Costa Rica
[5] NIAID, Infect Dis Lab, Div Intramural Res, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
ANTIBODY-DEPENDENT ENHANCEMENT; VIRUS-INFECTION; CLINICAL-EVALUATION; VACCINE; DISEASE; MOSQUITO; PATHOGENESIS; FEVER; MODEL;
D O I
10.1093/infdis/jis351
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Dengue is a systemic arthropod-borne viral disease of major global public health importance. At least 2.5 billion people who live in areas of the world where dengue occurs are at risk of developing dengue fever (DF) and its severe complications, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Repeated reemergences of dengue in sudden explosive epidemics often cause public alarm and seriously stress healthcare systems. The control of dengue is further challenged by the lack of effective therapies, vaccines, and point-of-care diagnostics. Despite years of study, even its pathogenic mechanisms are poorly understood. This article discusses recent advances in dengue research and identifies challenging gaps in research on dengue clinical evaluation, diagnostics, epidemiology, immunology, therapeutics, vaccinology/clinical trials research, vector biology, and vector ecology. Although dengue is a major global tropical pathogen, epidemiologic and disease control considerations in this article emphasize dengue in the Americas.
引用
收藏
页码:1121 / 1127
页数:7
相关论文
共 50 条
  • [1] NS5 of Dengue Virus Mediates STAT2 Binding and Degradation
    Ashour, Joseph
    Laurent-Rolle, Maudry
    Shi, Pei-Yong
    Garcia-Sastre, Adolfo
    [J]. JOURNAL OF VIROLOGY, 2009, 83 (11) : 5408 - 5418
  • [2] Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification
    Balsitis, Scott J.
    Williams, Katherine L.
    Lachica, Ruben
    Flores, Diana
    Kyle, Jennifer L.
    Mehlhop, Erin
    Johnson, Syd
    Diamond, Michael S.
    Beatty, P. Robert
    Harris, Eva
    [J]. PLOS PATHOGENS, 2010, 6 (02)
  • [3] Tropism of Dengue Virus in Mice and Humans Defined by Viral Nonstructural Protein 3-Specific Immunostaining
    Balsitis, Scott J.
    Coloma, Josefina
    Castro, Glenda
    Alava, Aracely
    Flores, Diana
    McKerrow, James H.
    Beatty, P. Robert
    Harris, Eva
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2009, 80 (03) : 416 - 424
  • [4] Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial
    Beckett, Charmagne G.
    Tjaden, Jeffrey
    Burgess, Timothy
    Danko, Janine R.
    Tamminga, Cindy
    Simmons, Monika
    Wu, Shuenn-Jue
    Sun, Peifang
    Kochel, Tadeusz
    Raviprakash, Kanakatte
    Hayes, Curtis G.
    Porter, Kevin R.
    [J]. VACCINE, 2011, 29 (05) : 960 - 968
  • [5] The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity
    Beltramello, Martina
    Williams, Katherine L.
    Simmons, Cameron P.
    Macagno, Annalisa
    Simonelli, Luca
    Quyen, Nguyen Than Ha
    Sukupolvi-Petty, Soila
    Navarro-Sanchez, Erika
    Young, Paul R.
    de Silva, Aravinda M.
    Rey, Felix A.
    Varani, Luca
    Whitehead, Stephen S.
    Diamond, Michael S.
    Harris, Eva
    Lanzavecchia, Antonio
    Sallusto, Federica
    [J]. CELL HOST & MICROBE, 2010, 8 (03) : 271 - 283
  • [6] Development of a recombinant tetravalent dengue virus vaccine: Innmunogenicity and efficacy studies in mice and monkeys
    Clements, David E.
    Coller, Beth-Ann G.
    Lieberman, Michael M.
    Ogata, Steven
    Wang, Gordon
    Harada, Kent E.
    Putnak, J. Robert
    Ivy, John M.
    McDonell, Michael
    Bignami, Gary S.
    Peters, Iain D.
    Leung, Julia
    Weeks-Levy, Carolyn
    Nakano, Eileen T.
    Humphreys, Tom
    [J]. VACCINE, 2010, 28 (15) : 2705 - 2715
  • [7] Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans
    Dejnirattisai, Wanwisa
    Jumnainsong, Amonrat
    Onsirisakul, Naruthai
    Fitton, Patricia
    Vasanawathana, Sirijitt
    Limpitikul, Wannee
    Puttikhunt, Chunya
    Edwards, Carolyn
    Duangchinda, Thaneeya
    Supasa, Sunpetchuda
    Chawansuntati, Kriangkrai
    Malasit, Prida
    Mongkolsapaya, Juthathip
    Screaton, Gavin
    [J]. SCIENCE, 2010, 328 (5979) : 745 - 748
  • [8] Du Tertre Jean-Baptiste, HIST GEN ANTILLES HA, P1667
  • [9] Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine
    Durbin, Anna P.
    Kirkpatrick, Beth D.
    Pierce, Kristen K.
    Schmidt, Alexander C.
    Whitehead, Stephen S.
    [J]. VACCINE, 2011, 29 (42) : 7242 - 7250
  • [10] A 5′ RNA element promotes dengue virus RNA synthesis on a circular genome
    Filomatori, Claudia V.
    Lodeiro, Maria F.
    Alvarez, Diego E.
    Samsa, Marcelo M.
    Pietrasanta, Lia
    Gamarnik, Andrea V.
    [J]. GENES & DEVELOPMENT, 2006, 20 (16) : 2238 - 2249